"IPIX is partnered - publicly at least - with Evonik and CoreRx, and I think both would fall in the specialty pharmaceutical company category, and I'm sure they both have CDA's with IPIX."
I expect that you're right about the CDA part of that. CTIX/IPIX may even have a couple of dusty old CDA's with Dr. Reddy's (quoting from various Prs..."for the formulation of the Company’s defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections", "for the manufacturing of Prurisol™, the Company’s new drug candidate for the treatment of psoriasis"...and others..."the manufacturing of Kevetrin™, the Company’s novel cancer compound for multi-drug resistant cancers, has been completed under cGMP manufacturing conditions by Lyophilization Services of New England", "is pleased to report that its toxicology vendor, Toxikon Corporation, is currently presenting its poster “Bioanalytical Method for Kevetrin™” ").
And I'm glad that you agree that, when it comes to CDAs, quality is the priority versus quantity.
But the "nearing 20" CDA press release in question didn't just say "specialty pharmaceutical company". It said "specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates" which would take an awful lot of stretching in terms of the presumed intent and context of the statement it was in to include companies whose business in producing or formulating drug materials for IPIX required secrecy. That can't be what was meant here and so even though the magic number of 20 has no clearly specific meaning it couldn't honestly include your examples....
"The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;"....
....unless Evonik and CoreRx are manufacturers who make investments in their customers on the side.
Finally, since they tossed it into the formula that generated "nearing 20", what are the Company's "first-in-class drug candidates"? Are all their candidates "first-in-class" and what does it mean to say that a candidate is "first-in-class"? I would have thought that such a designation would be reserved for drugs that have been approved and in use.
Recently I was accused of being a lawyer (I'm not, thank you Ch_11) and told "It’s not worth the time to parse words." I don't agree and I'll bet you don't either. A Company's words are second only to its actions in terms of importance to investors. They SHOULD be parsed. And sometimes it's not just the Company's words that need parsing.
GL
But can it core A apple?
Yes Ralph, of course it can core A apple.
AI
